S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,296.89 (-0.07%)
DOW   33,547.24 (-0.35%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   104.07 (+1.27%)
T   14.99 (-0.13%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.29%)
GE   110.44 (-1.69%)
DIS   80.91 (+0.97%)
AMC   8.07 (+3.59%)
PFE   33.06 (+3.02%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
NYSEAMERICAN:CATX

Perspective Therapeutics (CATX) Stock Forecast, Price & News

0.28
+0.01 (+2.56%)
(As of 12:30 PM ET)
Compare
Today's Range
0.27
▼
0.28
50-Day Range
N/A
52-Week Range
0.21
▼
0.73
Volume
44,859 shs
Average Volume
661,620 shs
Market Capitalization
$77.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsHeadlinesShort InterestSocial Media

CATX stock logo

About Perspective Therapeutics (NYSEAMERICAN:CATX) Stock

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

CATX Price History

CATX Stock News Headlines

September 12, 2023 | finance.yahoo.com
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
August 30, 2023 | finance.yahoo.com
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
September 29, 2023 | PressReach (Ad)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
August 28, 2023 | finance.yahoo.com
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
August 11, 2023 | finanznachrichten.de
Perspective Therapeutics, Inc.: Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
August 11, 2023 | finance.yahoo.com
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
August 11, 2023 | finance.yahoo.com
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
August 11, 2023 | finance.yahoo.com
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
September 29, 2023 | PressReach (Ad)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
August 9, 2023 | finance.yahoo.com
Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
July 23, 2023 | finance.yahoo.com
CATX - Perspective Therapeutics, Inc.
June 27, 2023 | finance.yahoo.com
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
June 16, 2023 | finance.yahoo.com
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
June 8, 2023 | finance.yahoo.com
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference
May 24, 2023 | finance.yahoo.com
Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
May 19, 2023 | msn.com
Oppenheimer Maintains Perspective Therapeutics (CATX) Outperform Recommendation
May 16, 2023 | seekingalpha.com
Perspective Therapeutics reports Q1 results
May 16, 2023 | finanznachrichten.de
Perspective Therapeutics, Inc.: Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
May 15, 2023 | finance.yahoo.com
Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
May 15, 2023 | finance.yahoo.com
Perspective Therapeutics Announces Changes to the Board of Directors
See More Headlines
Receive CATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CATX Company Calendar

Last Earnings
8/11/2023
Today
9/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CATX
CUSIP
N/A
CIK
N/A
Web
www.isoray.com
Phone
(509) 375-1202
Fax
509-267-3670
Employees
91
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
-0.09
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,270,000.00
Net Margins
-239.46%
Pretax Margin
N/A
Return on Equity
-19.46%
Return on Assets
-17.83%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
3.72
Quick Ratio
3.59

Sales & Book Value

Annual Sales
$10.80 million
Price / Sales
7.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
0.45 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
280,570,000
Free Float
264,522,000
Market Cap
$75.75 million
Optionable
Not Optionable
Beta
1.61
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Johan M. Spoor (Age 51)
    CEO & Director
  • Mr. Jonathan R. Hunt (Age 56)
    CFO & Co-Principal Financial Officer
    Comp: $144.12k
  • Mr. Shane Cobb
    Exec. VP of Operations
  • Mr. Mark J. Austin CPA (Age 36)
    VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
  • Dr. Michael K. Schultz Ph.D.
    Chief Science Officer
  • Mr. Andrew Bright
    Exec. VP of Brachytherapy
  • Dr. Markus Puhlmann M.B.A. (Age 57)
    M.D., Chief Medical Officer
  • Mr. Amos Hedt BA
    PGradDip, Chief Bus. Strategy Officer
  • Dr. Frances L. Johnson M.D.
    Chief Innovation Officer
  • Mr. David Hauser Ph.D.
    Sr. VP of Clinical Operations

Key Competitors

View All Competitors













CATX Stock - Frequently Asked Questions

Are investors shorting Perspective Therapeutics?

Perspective Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,570,000 shares, a drop of 11.8% from the August 15th total of 1,780,000 shares. Based on an average daily trading volume, of 301,900 shares, the days-to-cover ratio is presently 5.2 days. Approximately 0.8% of the shares of the company are short sold.
View Perspective Therapeutics' Short Interest.

How were Perspective Therapeutics' earnings last quarter?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The company had revenue of $2.09 million for the quarter, compared to analyst estimates of $2.61 million. Perspective Therapeutics had a negative net margin of 239.46% and a negative trailing twelve-month return on equity of 19.46%.

What is Perspective Therapeutics' stock symbol?

Perspective Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CATX."

What is Perspective Therapeutics' stock price today?

One share of CATX stock can currently be purchased for approximately 0.27.

How much money does Perspective Therapeutics make?

Perspective Therapeutics (NYSEAMERICAN:CATX) has a market capitalization of $75.75 million and generates $10.80 million in revenue each year. The company earns $-7,270,000.00 in net income (profit) each year or -0.09 on an earnings per share basis.

How can I contact Perspective Therapeutics?

Perspective Therapeutics' mailing address is 350 HILLS STREET SUITE 106, RICHLAND WA, 99354. The official website for the company is www.isoray.com. The company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670.

This page (NYSEAMERICAN:CATX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -